Steroid sensitivity in the respiratory tract by Williams, Sanford
Boston University
OpenBU http://open.bu.edu
Theses & Dissertations Boston University Theses & Dissertations
2015
Steroid sensitivity in the respiratory
tract
https://hdl.handle.net/2144/16073
Boston University
	   	   	  
BOSTON UNIVERSITY 
 
SCHOOL OF MEDICINE 
 
 
 
 
 
Thesis 
 
 
 
 
STERIOD SENSITIVITY IN THE RESPIRATORY TRACT 
 
 
 
 
by 
 
 
 
 
SANFORD J.S. WILLIAMS, IV 
 
B.A., University of Virginia, 2013 
 
 
 
 
 
 
 
 
Submitted in partial fulfillment of the 
 
requirements for the degree of 
 
Master of Science 
 
2015  
	   	   	  
 
COPYRIGHT PAGE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© 2015 by 
 SANFORD J.S. WILLIAMS, IV 
 All rights reserved
	   	   	  
 
READER APPROVAL PAGE 
Approved by 
 
 
 
 
     First Reader   
  
 Vickery Trinkaus-Randall, Ph.D. 
 Professor of Biochemistry and Ophthalmology 
 Director, Cell and Molecular Biology Graduate Program 
  
 
 
 
 
Second Reader   
  
 William G. Teague, M.D. 
 Ivy Foundation Distinguished Professor of Pediatrics 
 Associate Director, Child Health Research Center, 
 Chief, Division of Respiratory Medicine, Allergy, and Immunology 
 UVa School of Medicine
	  	   iv 
ACKNOWLEDGMENTS 
I would like to sincerely thank, Dr. Gerald Teague, Dr. Debbie Shirley, Dr. John 
Steinke, Dr. Larry Borish and everyone else in the Pediatric, Asthma, and Allergy 
Division at The University of Virginia. Thank you for all your help and instruction, 
and for allowing me to be a part of this research. 
	  	   v 
 
STERIOD SENSITIVITY IN THE RESPIRATORY TRACT 
 
SANFORD J.S. WILLIAMS, IV 
 
 
ABSTRACT 
 
 Increasing evidence indicates that current clinical treatment and 
management of asthma in the United States does not sufficiently control the 
disease. The incidence of asthma is reaching record highs. Nonetheless, 
although a great emphasis is being placed on current asthma treatment 
practices, the number of asthmatic individuals experiencing exacerbations and 
living with uncontrolled asthma remains dangerously high. Currently, steroid 
treatment is the pharmacologic pillar of asthma management. However, current 
data suggests that numerous asthmatic individuals currently on steroid 
treatments are not experiencing improved disease symptoms while on the drugs. 
Presently, there is a relative absence of literature exploring mechanisms that 
possibly mediate steroid insensitivity in asthmatics. However, consideration of 
current literature does suggest that there may be an overlay between airway 
microbiome and steroid sensitivity. This study attempts to identify a possible 
relationship between airway bacterial burden and steroid sensitivity in asthmatics 
in the hopes of improving the medical management of asthma in the United 
States. 
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INTRODUCTION 
 
Over the course of the past ten years, the prevalence of asthma in the 
United States has seen a continuous, gradual increase. Current data suggests 
that this increase will continue into the next few years.1 The increased 
prevalence of asthma in America has led to a more concentrated focus by 
clinicians and medical researchers on the clinical management of asthma. 
Today, inhaled corticosteroid treatment serves as the cornerstone of asthma 
treatment and control.2 As recently as 2005, almost 70% of all therapy starts for 
American asthmatic patients were prescriptions for medications that contained 
inhaled corticosteroids.3 Additionally, current medical prescribing practices 
identify low doses of inhaled corticosteroids as the preferred monotherapy for 
asthma treatment in children with mild persistent asthma.4 The increasingly 
directed focus on inhaled corticosteroids as the primary therapy for asthma has 
lead to a continuous increase in their prescription over the past decade. Further, 
this increased utilization of inhaled corticosteroids has also been amplified by the 
increased prevalence of asthma in America. By 2004, the number of 
prescriptions for inhaled corticosteroids in the United States was almost five 
times higher than it was in 1991 (Figure 1).5 Even with the recent increase in the 
number of asthma diagnoses that we have seen in the United States, an 
increase this large over such a short time period strongly evinces the increased 
utilization of inhaled corticosteroids as therapeutic intervention. In essence, 
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inhaled corticosteroids are a pillar of the pharmacologic management of asthma 
in America. 
Figure 1: In a recent ecologic analysis of inhaled corticosteroid (ICS) dispensing in the 
United States from 1991-2004, a continuous annual increase in the number of ICS 
prescriptions was discovered. 
 Technically, the term corticosteroid refers to any steroid hormone within 
the class of hormones that is produced within the adrenal cortex of vertebrates. 
Consequently corticosteroids include both mineralocorticoids, such as 
aldosterone, and glucocorticoids, such as cortisol. While some clinically utilized 
steroid treatments such as dexamethasone do exhibit moderate 
mineralocorticoid effects, typically, these effects are not the therapeutically 
pertinent intended effects of steroid treatment.6 In clinical practice, and for the 
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purpose of asthma treatment, the term corticosteroid refers primarily to 
glucocorticoids and their derivatives, which exhibit glucocorticoid anti-
inflammatory effects. This increased utilization of inhaled corticosteroids as the 
primary therapeutic treatment for asthma results from their established benefits in 
controlling inflammation. “Asthma is typically responsive to treatment with inhaled 
or oral corticosteroids.”7 In patients who respond to ICS treatment, there is 
improvement of asthma control, lung function, and reduction in exacerbations. 
These improvements may partially be mediated by the inhibition of inflammatory 
cell function and the resultant decreased stimulation of epithelial cells. 7 The 
positive effects of glucocorticoids are physiologically mediated by their binding to 
cytoplasmic glucocorticoid receptors, which subsequently relocate to the nuclear 
compartment. There, activated glucocorticoid receptors are able to assist in the 
regulation of transcription for specific target genes.8  
The inhibitory effect of glucocorticoids on cytokine synthesis has been 
highlighted as a potentially critical mechanism of asthma control.  Steroids inhibit 
the transcription of a number of cytokines that are relevant in asthma, including 
interleukin (IL)-1, tumor necrosis factor α (TNFα), granulocyte/macrophage 
colony-stimulating factor (GM-CSF), IL-3, IL-4, IL-5, IL-6 and IL-8.8 Resultantly, 
through the inhibition of synthesis for some of the specific cytokines, such as IL-
5, steroids are also able to reduce the survival of inflammatory immune cells 
such as eosinophils, which are frequently implicated with asthma. After treatment 
with corticosteroids, asthmatic patients exhibit a marked reduction in the number 
	  4 
of eosinophils and an additional decrease in the number of mucosal mast cells.8 
Ultimately, through these pathways, steroid treatment typically leads to a 
decrease in the airway inflammation of asthma patients. Consequently, the 
decrease in airway inflammation usually accompanies improvements in 
ventilation and lung function. The positive effects of steroids become increasingly 
important when considering the strong presence of asthma in America and the 
concurrent adverse effects of the disease when it is left uncontrolled. 
In 2009, the American Academy of Allergy, Asthma and Immunology 
(AAAAI) estimated that about 25 million Americans had asthma. With an 
estimated total American population of 305 million that year, this accounted for 
greater than 8% of the entire United States population. Consideration of the 
pediatric subpopulation revealed that an even higher percentage of American 
children had been diagnosed with asthma by 2009. By that year, one in ten 
American children had been diagnosed with the disease.1 Further, the estimated 
25 million American asthmatics account for almost 11% of the 235 million people 
the World Health Organization estimates have asthma globally.9 It is irrefutable 
that the asthma has become a significant health issue in the United States. 
Nonetheless, the incidence of asthma alone does not sufficiently illustrate the 
substantial adverse health issues created by the disease. Those health issues 
become most apparent through the consideration of American mortality rates. 
Over the past few years we have seen a progressive annual increase in the 
number of mortalities due to asthma. In 2010, 3,345 Americans died due to 
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asthma. A year later in 2011, 3,404 Americans also died as a result of asthma. 
Following this trend, in 2012, 3,531 Americans died due to asthma. Further, 
within the group of 2012 asthma mortalities, 152 of the deaths were children 
fourteen years old and younger.10–12 
The gradual increase in American mortalities due to asthma suggests the 
persistence of problems with the established medical management and treatment 
of asthma in the United States. Despite new therapies and treatments for 
Asthma, mortalities due to the disease continue to occur in the American 
population. The persistence of deaths along with a recently established high 
incidence of uncontrolled asthma, can together be viewed as a representation of 
the overall exacerbation of asthma within the United States population.3 On a 
daily basis in the U.S., more than 5,000 patients are seen in the emergency 
department, 1,200 are hospitalized, and nine pass away. These numbers alone 
portray a clearly evident need for improved asthma control. The severity of this 
problem is emboldened by the increasing incidence of asthma. In 2001, the 
incidence of asthma was only about 1 out of 15 Americans; by 2009 that 
incidence had risen to a ratio of about 1 in 12 Americans. Startlingly, the 
aforementioned pediatric rate of incidence of approximately 10% in 2009 also 
represented an increase from 8.7% in 2001. However, in order to fully 
understand the gravity of this increased incidence, it is necessary to consider the 
disease, it’s treatment, and it’s impact on the United States health care system in 
greater detail.   
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Asthma is a disease characterized by chronic inflammation of the airways, 
immune cell recruitment, and airflow limitation. Progressive uncontrolled asthma 
exacerbations can potentially lead to severe asthma attacks, acute respiratory 
failure, and ultimately death. In a study published in The Journal of Asthma in 
2005, researchers discovered that almost 65% of all asthmatics were using 
controller medications that contained inhaled corticosteroids. Nonetheless, in this 
prospective study, which comprised almost 60,000 asthmatic patients, almost 
three quarters of the patient population surveyed reported symptoms consistent 
with a lack of asthma control.3 Although inhaled corticosteroids frequently serve 
as the hypothetical “front line” of asthma treatment, many asthmatic patients on 
these medications still live with uncontrolled asthma. “Although most patients 
with a diagnosis of asthma can be adequately treated with a combination therapy 
of inhaled corticosteroids and a bronchodilator…there is a core of patients whose 
asthma remains uncontrolled despite being on these treatments.”13 A proposed 
cause of this persistent uncontrolled asthma in many patients is corticosteroid 
insensitivity or resistance. Corticosteroid resistance in asthmatics had been 
described and characterized as early as the 1960s: “A small proportion of 
patients with asthma fail to respond even to high doses of oral glucocorticoids. 
Glucocorticoid resistance was first highlighted in a report by Schwartz and 
colleagues in 1968, who described six patients with asthma who failed to 
respond to even high doses of systemic steroids...”14 While insensitivity to 
steroids has been recognized and identified in other inflammatory diseases, it 
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has been studied most carefully in asthma since it is relatively easy to assess the 
clinical response of asthmatics to steroid treatment. Nonetheless, although 
asthmatic steroid sensitivity study began to expand in the 1960s, the first formal 
definition of “corticosteroid-resistant asthma” was not proposed until years later in 
the early 1980s. Asthmatic patients were diagnosed with corticosteroid-resistant 
chronic asthma when there was no record of their forced expiratory volume in the 
first second (FEV1) ever increasing by more than 15% after a week long course 
of high prednisolone doses (20 mg or more) daily by mouth.15 As asthma 
becomes established as a more serious health issue in The United States, the 
necessity of characterizing corticosteroid responsiveness in asthma treatment 
becomes increasingly pronounced. This need becomes even more prominent 
when we direct our focus on the U.S. pediatric population, which by the numbers 
is the demographic most significantly affected by asthma. In 2009, a greater 
percentage of children had asthma than adults (10% vs. 8%). Furthermore, within 
this fraction of children with asthma, 57% of those affected had attacks in 2009 
compared to 51% of adults.1 
In recent years asthma’s impact on the American pediatric population has 
become increasingly severe. Over the past few years, we have seen an 
increased incidence of pediatric fatalities resulting from asthma. However, further 
research shows that this increase is not necessarily a new phenomemon. In the 
decade leading up to 1998, pediatric mortality due to asthma doubled. According 
to a research article published in Environmental Health Perspectives in 1998, 
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and a newer article published in 2003, asthma is one of the chronic conditions 
that have come to be referred to as the “new pediatric morbidity.”16,17 Within this 
group, asthma’s severity is paralleled to those of a few other health conditions 
more traditionally seen as threatening, including: pediatric cancers, 
neurodevelopmental and behavioral disorders, and certain congenital defects. All 
of the conditions and diseases comprising this group present serious adverse 
health consequences to pediatric patients. Additionally, each condition also 
contributes significantly to the burden of health care expenses in the United 
States. The importance of characterizing corticosteroid responsiveness in 
asthmatics is emboldened by the consideration of the economic costs associated 
with the disease. As early as 1997, the total estimated cost of pediatric asthma 
was already estimated to be approximately $2 Billion.16 With the incidence of 
both adult and pediatric asthma seeing an upsurge over the last decade, those 
costs have very likely also seen a sharp increase. The subset of the asthmatic 
population that exhibits corticosteroid insensitivity consumes the majority of the 
healthcare costs for asthma.13 A better understanding of asthmatic corticosteroid 
responsiveness would lead to improved disease management, and the alleviation 
of some costs associated with the disease. Consideration of the economic 
expenses associated with asthma identification, treatment, and management 
serve as a relatively effective quantitative measure of asthma’s impact on our 
society. 
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Qualitatively, asthma has established a lasting, continuous effect on both 
our society, and our health care system. As a result, clinicians and researchers in 
the United States have worked to establish clear guidelines for the clinical 
management and treatment of asthma. In 2007, the National Asthma Education 
and Prevention Program (NAEPP) of the National Heart, Lung, and Blood 
Institute published its third set of clinical practice guidelines for the diagnosis and 
management of asthma.18 In a basic sense, asthma control is the degree to 
which asthma symptoms are minimized through treatment. The updated 
guidelines emphasize the importance of asthma control through therapeutic 
intervention with inhaled corticosteroids serving as a focal point of treatment. 
However, a paper assessing the efficacy of the previous (similarly structured) 
guidelines yielded surprisingly negative results. Poor clinical asthma control 
persisted in patients even after increased implementation of the 
recommendations in these guidelines.3 Increased implementation of asthma 
treatment guidelines and adherence to their recommendations for the therapy of 
more than 60,000 patients raised the use of corticosteroids by 52%. Further, the 
assessment of physician prescribing practices with the previous guidelines 
revealed extremely high us of oral corticosteroids with them being utilized very 
frequently as relievers and also sometimes as long-term controllers. Additionally, 
the study determined that almost half of the patients with uncontrolled asthma 
who reported the use of controller therapy were using controller medications that 
contained a corticosteroid.  
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In depth exploration of the proposed treatment guidelines for asthma 
confirms the high prevalence of corticosteroid containing medications in 
therapeutic treatment plans. Interestingly, treatment has progressed to a point 
where the researchers and clinicians of The American Thoracic Society have 
begun to define severe asthma by the necessity for corticosteroid intervention. 
“Severe asthma is widely recognized as a major unmet need. It is defined as 
asthma that requires treatment with high-dose inhaled corticosteroids and a 
second controller and/or systemic corticosteroid to prevent it from becoming 
‘uncontrolled’, or that remains ‘uncontrolled’ despite this therapy.”13 
Consequently, about one-third of severe asthmatic patients take regular doses of 
oral corticosteroids, and over half needed more than three bursts of oral 
corticosteroids in the past year.19,20 The most recent guidelines for the diagnosis 
and management of Asthma released by the NAEPP reflect the established 
confidence in corticosteroid treatment, recommending that inhaled corticosteroids 
continue their use as the preferred long-term control therapy across all age 
groups.18 Nonetheless, these guidelines fail to fully address the absence of 
response to corticosteroid treatment in countless asthmatics.  
In essence, asthma has recently become established as an extremely 
significant health issue in the United States. Nonetheless, although a plethora of 
financial resources are being utilized in numerous research efforts focused on 
the treatment and management of asthma, current treatment strategies in place 
are not sufficiently controlling the disease in the American population. While 
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corticosteroid treatment serves as a moderately effective therapy for many 
asthmatics, the subpopulation of asthmatics who do not respond to inhaled 
corticosteroid treatment have become a new focal point of recent research 
efforts. An increased exploration and understanding of asthmatic steroid 
insensitivity will hopefully lead to improvements in American asthma 
management. Concordantly, In order to fully characterize asthmatic steroid 
sensitivity, it is necessary to explore the biological mechanisms that mediate the 
physiologic respiratory responses to steroid treatment. While there is some 
recent literature available that has explored corticosteroid responsiveness in 
asthma, there has been a primary focus on the steroid response in peripheral 
blood mononuclear cells (PBMCs).21,22  
The National Heart and Lung Institute hypothesized in 2006 that the poor 
response of severe asthmatics to corticosteroids results from the reduced ability 
of the drugs to inhibit the release of cytokines from activated PBMCs. They 
discovered data to support this conclusion by examining the release of specific 
inflammatory cytokines by PBMCs before and after exposure to the steroid 
dexamethasone. Interestingly, severe asthmatics showed less suppression of 
cytokine release by dexamethasone than patients with non-severe asthma. With 
a similar approach, a research article published in 2013 by a team of physicians 
from Colorado published data that suggested the airway microbiome of subjects 
could influence their corticosteroid responsiveness. In order to identify the 
functional interaction of bacteria with corticosteroid responsiveness, they utilized 
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peripheral blood monocytes and macrophages from the bronchial alveolar lavage 
(BAL) fluid.22 Incubation of the BAL macrophages with Haemophilus 
parainfluenzae (H. para) led to an in vitro reduction of their response to 
corticosteroids. Exploration of their experiments suggests the possibility of an 
altered response to corticosteroid therapy in the presence of specific physiologic 
airway conditions. If confirmed, the presence of a relationship between airway 
microbiome and steroid sensitivity could greatly advance the clinical 
understanding of steroid resistance in refractory asthma. However, although 
valuable, the results presented in these two example studies do not wholly 
characterize the physiologic dynamics and mechanisms of altered steroid 
sensitivity in asthmatics; they are unable to completely do so because of their 
emphasis on PBMCS. Recent research projects have suggested that epithelial 
cells may be one of the most important targets for inhaled glucocorticoids in 
asthma.8 Nonetheless, the approach taken in these two studies constitutes the 
rule rather than the exception in the majority of asthmatic steroid sensitivity 
studies.  Up to this point, research on patient responsiveness to ICS has focused 
on systemic and peripheral markers in the blood such as PBMCs and 
eosinophils. “It has been known for a while that blood eosinophilia is a good 
marker of a therapeutic response to corticosteroids.”13 However, in order to 
establish a more direct, concrete, and basic understanding of ICS insensitivity in 
asthmatics, it seems logical to assess the response elicited at their immediate 
site of action, epithelial cells.23 
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In 2007, Dr. Prescott Woodruff and his research team at the University of 
California, San Francisco (UCSF) were able to identify four specific genes 
associated with the therapeutic response of asthma patients to corticosteroid 
treatment.7 The four genes identified were chloride channel, calcium activated, 
family member 1(CLCA1), periostin, serine peptidase inhibitor clade B member 2 
(serpinB2), and FK506-binding protein 51 (FKBP51). Each of these genes plays 
a unique role in the expression and management of asthma. CLCA1 in tandem 
with IL13 leads to mucous cell metaplasia, and excess mucous production in 
airways, contributing to the clinical symptoms of asthma. Additionally, it is 
postulated to play a role in airway hyperreactivity and eosinophil accumulation in 
asthma.24,25 Periostin, which is induced by IL13, contributes to the establishment 
of chronic airway inflammation and remodeling, fundamental features of classic T 
helper 2 (TH2) driven asthma.26 The physiologic function of inflammation-
associated serpinB2 has not yet been fully identified. However, it is a proposed 
regulator of the T helper 1 (TH1) immune response and promoter of fibrin 
formation and deposition leading to the pathogenesis of airway 
hyperresponsiveness.7,27 Finally, FKBP51 is a postulated player in the negative 
feedback loop in place to limit the glucocorticoid receptor response to 
corticosteroids in vivo. In essence, these four genes each represent discrete 
aspects of asthma persistence and control.  
Through the use of gene expression microarrays, Dr. Woodruff’s research 
team explored the differences in the levels of expression for these genes in 
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asthmatics before and after corticosteroid treatment. They discovered that 
CLCA1, serpinB2, and periostin were markedly up-regulated in asthmatic 
patients compared to their expression levels in healthy patients and smokers, 
who served as the disease controls. Subsequently, the team discovered that 
corticosteroid treatment down-regulated the expression of these three genes 
while simultaneously up-regulating the expression of FKBP51. Further the 
response of these specific genes to corticosteroid treatment served as a strong 
indicator of a positive asthmatic response to corticosteroid treatment. 
Additionally, high baseline levels of FKBP51 served as indicators of a poor 
asthmatic response to corticosteroid treatment. Another aspect of the study 
explored the role of IL-13, an anti-inflammatory cytokine often implicated in 
asthma, in the regulation of the gene expression levels of the above four genes.  
“We describe periostin, serpinB2, and CLCA1 as biomarkers of classic 
IL-13-driven, corticosteroid-responsive asthma and as potential 
mediators of disease. These proteins can plausibly be inserted in 
pathways of pathology in the epithelium and submucosa. In addition, 
we identify FKBP51 as a biomarker of corticosteroid responsiveness 
and a potential mediator of corticosteroid-resistant disease. 
Finally, we demonstrate that bronchial epithelial cells are 
direct targets both for IL-13-mediated gene induction in asthma, 
and for corticosteroid repression of those induced genes in treatment 
of this disease.”7  
 
In-vitro exposure of airway epithelial cells to IL-13 lead to increased airway 
epithelial cell expression of CLCA1, periostin, and serpinB2. However, this effect 
was suppressed by parallel treatment of the epithelial cells with corticosteroids, 
which also induced the expression of FKBP51. The expected response of these 
specific genes to corticosteroid treatment served as a strong indicator of a 
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positive asthmatic clinical response to corticosteroid treatment. Additionally, high 
baseline levels of FKBP51 served as indicators of a poor asthmatic clinical 
response to corticosteroid treatment.  
Quick exploration of the existing literature on asthmatic steroid sensitivity 
indicates that the focus placed by Dr. Woodruff and his team on the response of 
bronchial epithelial cells represents a relatively novel approach. Further, the 
findings evinced by this data strongly suggest possible ties between the genes 
CLCA1, periostin, serpinB2, FKBP51, and a clinical response to steroid treatment 
at the level of bronchial epithelial cells. The data published on these 4 genes in 
concert with research exploring the possible effect of airway microbiome on 
steroid sensitivity sets the stage for a study pursuing a possible overlap between 
the two. Moreover, the high prevalence of pediatric asthma in America and the 
detrimental effects of the disease within the pediatric population distinguish 
American children as an ideal study demographic. At UVa’s department of 
Pediatric Respiratory Medicine & Allergy, our research team has hypothesized 
that the presence of bacteria in the airways of asthmatic children has lead to 
direct alterations in their cellular responsiveness to steroid treatment. It is our 
hope that through this study we will improve current understanding of steroid 
insensitivity, and ultimately elicit improvements in future asthma treatment 
strategies.  
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SPECIFIC OBJECTIVES 
The primary purpose of this study is to apply sensitive molecular 
techniques to study the impact of the quantitative burden of bacteria on asthma 
control in the study population. In doing so, we will compare clinical features, 
lung function, circulating biomarkers, and BAL constituents, including cytokine 
profiles, in children and young adults who undergo diagnostic bronchoscopy, with 
and without asthma. 
Succinctly, this research study has four specifically delineated objectives. 
The first of those four objectives is to compare the relative burden of bacteria in 
the lower airways of children and young adults with asthma versus non-asthmatic 
controls. This will allow us to assess any possible differences present in the 
airway bacterial population of asthmatic subjects and non-asthmatic controls. 
Additionally, it will allow us to quantify the bacterial burden using molecular 
techniques and search for the possible co-presence or absence of common 
respiratory viruses from the BAL. Finally, this objective will allow cluster analysis 
of inflammatory cytokines from the BAL. 
Our second specific objective is to determine if the relative burden of 
bacteria in the lower airways of asthmatic children and young adults is a 
determinant of control and severity. Consequently, we hope to explore any 
possible indications that bacterial burden can suggest for the management of 
asthma with steroids, and the response of specific patients to steroid treatment. 
Our third specific objective is to compare the relative burden of specific bacteria 
	  17 
in the upper and lower airways of the population being studied. Differences 
between the two areas of the airway could also quite significantly contribute to 
the severity and control of asthma in our subjects. Finally, our last specific object 
is to determine the presence of defects in innate immunity of respiratory 
epithelium in asthmatics that would predispose the population being studied to 
colonization or infection with bacterial (and viral) pathogens.
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METHODS 
This is a small, exploratory study aimed to enroll pediatric patients 
requiring bronchoscopy for clinical indications over a 12-24 month period. We 
estimate that approximately 120 pediatric patients will undergo bronchoscopy 
over the next year, but not all patients will be eligible or will consent to 
participate. Our estimated sample size for this study is 90 subjects. We plan to 
enroll 100 subjects, assuming a 10% drop out rate. We estimate that there will be 
2 asthmatic patients undergoing bronchoscopy for every non-asthmatic patient. 
In addition to comparing the groups, the study will also provide estimates of 
variation of the bacterial burden; these estimates will be valuable in planning a 
larger study of the effects of bacterial burden in patients with asthma.  
The University of Virginia Severe Asthma and Respiratory Medicine clinics 
provide comprehensive care for children and young adults with respiratory 
diseases, and are tertiary referral centers for a broad region encompassing 
Virginia and the entire Mid-Atlantic area. Conditions such as asthma (including 
severe asthma), cystic fibrosis, immotile cilia disorders, daily cough, recurrent 
pneumonia, allergies, chronic sinus disorders, and sleep related respiratory 
disorders are evaluated and treated. Recruitment of patients will occur during 
clinic visits. Alternatively, participants may be asked to return to the Clinical 
Research Unit, or other designated location to complete enrollment and 
start/complete study visit 1. The UVa Pediatric Respiratory Medicine clinic also 
has a satellite clinic in Lynchburg, at the Virginia Baptist Hospital. Subjects seen 
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at this clinic, in whom bronchoscopy is recommended for clinical indications, will 
also be eligible for participation. These subjects will be identified by the study 
involved doctor caring for them at the Lynchburg site, and consent will be 
obtained via the phone or on the day of bronchoscopy, at UVa. 
This is a prospective, convenience, case-control study of asthmatic and 
non-asthmatic children and young adults undergoing bronchoscopy for clinical 
indications. Potential enrollees come from a broad geographic region and are 
diverse with regards to asthma features, ethnicity, and socio-economic status. In 
ongoing work we compared asthma features in a convenience sample of children 
who underwent a research-imaging feature to those who did not. There was no 
difference, indicating we can enroll an appropriate sample with features 
resembling those who compose the referral population to our medical center. The 
sample will be skewed towards children referred for specialty care and who have 
been refractory to community-based treatment. For the purposes of this study, 
poorly controlled asthma refers to the extent by which clinical symptoms of 
asthma have not been reduced or removed by treatment.  
Participants will be recruited from among the population of children and 
young adults (up to age 28 at the time of enrollment) presenting to the UVa 
Pediatric Pulmonology clinic requiring bronchoscopic evaluation for clinical 
indications. UVa Institutional Review Board will approve all study procedures and 
the consent form in advance. Participants will be invited to participate in a 
sequential manner, without regards to sex, race or ethnicity. Enrollment in other 
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observational trials is allowable, but co-enrollment in interventional studies 
currently not approved for the treatment of asthma by the FDA will not be 
permitted if the intervention will be administered 28 days prior to bronchoscopy. 
Participants must be deemed clinically stable enough to undergo the procedure 
as determined by the bronchoscopist.  
For asthmatics undergoing bronchoscopy, our inclusion criteria dictates 
that included subjects must be from 0-28 years old at the time of enrollment, 
must be undergoing bronchoscopic evaluation for clinical indication, and must be 
able to understand and complete the required study procedures. Additionally, 
these subjects must have current asthma as defined by the following guidelines: 
a) Pre-school children (0-5 years)  
a. Intermittent cough, wheeze, chest symptoms not restricted to 
respiratory infections AND a positive asthma predictive index, 
defined as one of the following: 
b. Documented eczema, or known milk sensitivity, OR 
c. Peripheral eosinophilia (Eosinophilia >/= 4% on a peripheral blood 
smear), OR 
d. An elevated total serum IgE > 140 IU/ml, OR 
e. One more allergen-specific IgE titers > 1.5 units for any food or 
inhalant, OR 
f. A positive family history of asthma or allergy in a parent or sibling. 
 
b) Temporal wheezing (0-6 years) 
Children with either of the following, but a negative asthma predictive 
Index (as defined above), can also be enrolled into the study, but will 
be analyzed separately from those children with a positive asthma 
predictive index 
• Episodic viral wheeze: wheeze during discrete time periods, often 
in association with clinical evidence of a viral cold, with the 
absence of wheeze between episodes 
• Multiple-trigger wheeze: wheeze that shows discrete 
exacerbations, but also symptoms between episodes 
c) School-Age Children (5-28 years at time of enrollment) 
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Clinical diagnosis of asthma, as confirmed by a pediatric pulmonologist or 
pediatrician with asthma expertise, and including evidence of variable 
airflow obstruction, bronchial hyper-responsiveness, airway inflammation 
and/or response to therapy) 
 
The exclusion criteria for asthmatic subjects dictates that subjects may not 
be enrolled in the study if they are enrolled in an interventional trial of a non-FDA 
approved asthma treatment, involving administration of the intervention within 28 
days of bronchoscopy. Additionally, they may not be enrolled if they exhibit any 
other condition(s) that in the opinion of the investigator would jeopardize the 
safety or rights of a participant, or would render the participant unable to comply 
with the protocol. Subjects will be stratified by asthma severity, which will be 
defined according to the recent ERS/ATS task force on severe asthma as 
“asthma that requires treatment with high dose corticosteroids (either inhaled 
and/or systemic) PLUS a second controller to remain controlled or may be 
uncontrolled despite such therapy.”28 This definition assumes co-morbidities have 
been recognized and appropriately addressed and that the patient has been 
under the care of an asthma specialist.  Subjects will also be stratified by asthma 
control. Poorly controlled asthma will be defined as a score on the Asthma 
Control Test (ACT) as ≤ 19 units, or A score on the Juniper Asthma Control 
Questionnaire (ACQ) as ≥ 1.5 units in the face of appropriate inhaled or oral 
corticosteroid treatment for at least three months.  
For non-asthmatics undergoing bronchoscopy we have similar inclusion 
and exclusion criteria. Non-asthmatic children and young adults with significant 
respiratory symptoms who undergo bronchoscopy will also be invited to 
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participate. This sample will primarily include patients with laryngomalacia, 
trachea-malacia, bronchomalacia, suspected congenital anomalies, suspected 
aspiration of foreign bodies, and complications of congenital heart disease. 
Inclusion criteria dictates that subjects must be 0-28 years of age at the time of 
enrollment, and they must also be undergoing bronchoscopic evaluation for 
clinical indication for respiratory symptoms other than poorly controlled asthma. 
Standard clinical indications for diagnostic bronchoscopy and BAL are: recurrent 
or persistent pneumonia, stridor, recurrent croup, suspected aspiration 
syndromes, congenital anomalies of the lungs or airways, suspected aspiration of 
foreign objects, examination findings of laryngomalacia or tracheomalacia, 
bronchiectasis, suspect ciliary dyskinesia syndromes, respiratory complications 
of congenital heart disease, suspected airway compression syndromes by 
vascular ring or sling anomalies.  
The exclusion criteria for non-asthmatic patients dictates that subjects 
cannot be included if they display physician diagnosed asthma or episodic 
wheeze (e.g., viral induced)/ multiple-trigger wheeze (for children less than or 
equal to 6 years of age), based on the documented presence of one or more of 
the following characteristics in the previous year29:  i Physician diagnosis of asthma ii Use of albuterol for coughing or wheezing episodes (prescribed by a 
physician) iii Use of a daily controller medication  
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iv Step-up plan including use of albuterol or short-term use of inhaled 
corticosteroids during illness v Use of prednisone for asthma exacerbation 
Additionally, patients will be excluded from the study if they are enrolled in an 
interventional trial of a non-FDA approved asthma treatment, involving 
administration of the intervention within 28 days of bronchoscopy. Finally, any 
other condition(s) that in the opinion of the investigator would jeopardize the 
safety or rights of a participant or would render the participant unable to comply 
with the protocol also excludes. 
Over the course of the enumerated 12-24 month period, we plan to enroll 
children and young adults presenting to the University of Virginia (UVa) Pediatric 
Respiratory Medicine outpatient clinic or Virginia Baptist Hospital outpatient clinic 
with respiratory symptoms and indications for a diagnostic bronchoscopy. 
Individuals with either asthma or non-asthmatic respiratory disorders who satisfy 
our above criteria and undergo bronchoscopy at UVa will be enrolled. Enrolled 
subjects from our target populations will participate from the time of enrollment 
until the time that bronchoscopy is completed. Individuals who undergo more 
than one planned bronchoscopy in a one-year period will be asked to have 
samples and data collected at the time of each bronchoscopy.  
During the initial visit, a study team member will present a detailed 
overview of the study and obtain informed consent. Written consent will be 
obtained for all subjects who decide to participate in this study. However, as 
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outlined in the IRB Application, some subjects will be consented in person, while 
others will be consented over the phone. In addition, a detailed database 
containing very thorough background information for each enrolled subject will be 
compiled through questionnaires completed during the initial visit. Asthma control 
will be determined by responses to a number of assessments including the ACT, 
or in young children the children’s ACT (cACT), and the Asthma control 
questionnaire, a simple questionnaire to measure the adequacy of asthma 
control and change in asthma control which occurs either spontaneously or as a 
result of treatment. Additionally, enlisted subjects will be given the Pediatric 
Asthma Quality of Life Questionnaire and the Pediatric Asthma Caregiver’s 
Quality of Life Questionnaire. The subject will give verbal responses to these 
questionnaires, and a clinical research coordinator will complete the 
questionnaires for subjects who are consented over the phone. Questionnaires 
will only be administered after consent is obtained.    
During the second visit, diagnostic bronchoscopy will be done at UVa. The 
surgery will take place in the procedure room of the UVa operating suites by an 
experienced physician with board certification who is credentialed to perform the 
procedure. Institutional standard of care practices will be followed. Furthermore, 
bronchoscopy and BAL will be performed according to recommendations as 
previously described.  In particular, procedural measures will be taken to limit 
contamination risk. Pediatric bronchoscopy will be performed under general 
anesthesia (sevoflorane and dexmetomidine) using a laryngeal mask airway and 
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flexible bronchoscope. The bronchoscope is advanced and wedged into a 
segmental bronchus, typically in the right middle lobe. A standard volume of 
sterile normal saline warmed to 37 degrees C is flushed at a volume of 1 cc per 
kg body weight up to 50 cc maximum into the segment. The effluent fluid is 
typically 28 to 40% of the instilled fluid volume and collected by suction in a 
sterile trap. Eligibility will be reviewed prior to collection of study samples. Clinical 
samples of BAL fluid will be divided out for clinical laboratories and transported to 
the designated laboratory area for processing and storage. Leftover BAL fluid will 
be used for the research purposes described in this protocol. Remaining BAL 
fluid of subjects who consent will be banked for future research. Per routine 
standard of care in our Pediatric Pulmonology practice, all patients undergoing 
bronchoscopic evaluation may have BAL fluid evaluated for the presence of 
bacterial pathogens by culture, respiratory viral pathogens by Polymerase Chain 
Reaction (PCR), cell count differentials, cytopathology and other clinically 
indicated testing.  
It is standard procedure in clinical bronchoscopy of children to obtain a 
brush cytology sample of the airway surface near the carina for the purposes of 
cytological evaluation of inflammation, infection, and ciliary motion. Normally one 
or possibly two brush samples are obtained and submitted for analysis 
depending on sample quality and yield. In this study an additional brush sample 
will be taken to the research laboratory of Dr. Larry Borish where the epithelial 
	  26 
cells will be assessed on their corticosteroid responsiveness. Leftover samples 
will be banked for future unspecified research. 
Molecular techniques to detect bacteria will be performed in the research 
laboratory of Dr. Fernando Ruiz. Brush samples containing airway epithelial cells 
will be submitted to the laboratory of Dr. Larry Borish at the University of Virginia 
for analysis of genetically-determined, biochemical, and immunological factors as 
they relate to infection and the human immune response. The epithelial cells 
yielded by bronchoscopy will be used to analyze corticosteroid responsiveness. 
Additionally peripheral blood will be stored in a departmental freezer for future 
analyses after appropriate processing. Peripheral blood mononuclear cells may 
be stored and frozen in the Borish laboratory. Cytokine measurements will be 
performed using multiplex technology by a faculty member within the department 
of Pulmonary/Allergy Medicine, depending on availability of resources.  
Candidate cytokine profiles include those associated with Th1 inflammation 
(interferon gamma), fibrosis (TGF beta), Th2 inflammation (IL-4, IL-5, IL-13), 
Th17 inflammation (IL-8, IL-17) and epithelial derived cytokines (IL-25, IL-33, 
TSLP).  
Upon receipt of the bronchoscopy epithelial cell brush in the Borish 
Laboratory, the brush will be immersed for ten minutes in 1 mL of dilute trypsin in 
a standard 15 mL Falcon polypropylene conical tube. The dilute trypsin is ideal 
for extracting the epithelial cells from the brush by disturbing the physical 
adhesion of the cells to the brush without modifying the biological makeup of the 
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cells. Subsequently, the cell containing trypsin solution will be neutralized with 1 
mL of trypsin neutralizing solution, and spun in a centrifuge for 5 minutes at 4000 
rotations per minute. This will separate the cells from the now neutral solution 
and create a cell pellet at the bottom of the conical tube. Following the removal of 
the supernatant, the cell pellet will be resuspended in 650 µL of Clonetics 
bronchial epithelial cell basal growth medium. The suspended solution of 
epithelial cells from the bronchoscopy will subsequently be evenly aliquoted by 
volumes of 100 µL into six wells of a 96 well polystyrene flat bottom cell culture 
cluster plate. After the suspended epithelial cells are plated, five of the wells will 
be exposed to varying concentrations of dexamethasone ranging from 10-10 
mol/L to 10-6 mol/L, and one control well will not be exposed to any steroids. After 
24 hours of incubation at 37° C, the cells will be extracted from the surface of the 
wells with 50 µL of dilute trypsin. Following the extraction of the cells, the solution 
will be neutralized with 50 µL of trypsin neutralizing solution, and transferred to 
1.5 mL polypropylene microcentrifuge tubes which will be centrifuged for 5 
minutes at 4000 rotations per minute to isolate a cell pellet. Subsequently, we will 
begin the process of RNA extraction from the cells within the pellet. 
Total RNA will be extracted from the epithelial cells using the RNA Bee - 
RNA Isolation Reagent kit (Oxfordshire, UK). Conversion of the mRNA to cDNA 
will be performed using a Taqman Reverse Transcription kit (Roche, Branchburg, 
NJ). Briefly, 200ng of RNA will be added to each reaction along with oligodT 
primers, 5.5 mM MgCl2, 2 mM dNTPs, RNasin, and reverse 
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transcriptase. Reactions will go through one cycle of 10 min at 25° C, 30 min at 
48° C and 5 min at 95° C in a Bio-Rad iCycler thermocycler (Bio-Rad, Hercules, 
CA). The cDNA will then be amplified by PCR. 
We will then utilize real time PCR to quantify CLCA1, FKBP51, periostin, 
and SerpinB2 mRNA levels in both unexposed epithelial cells and epithelial cells 
exposed to varying concentrations of dexamethasone. The housekeeping gene 
Human Elongation Factor-1 Alpha (EF1a) will be used as an internal control for 
normalization of mRNA levels, after cDNA is prepared as 
described. Amplification of CLCA1, FKBP51, periostin, and SerpinB2 will be 
performed using their corresponding probe/primers pairs.  PCR reactions 
consisted of iQ Supermix (Bio-Rad), fibroblast cDNA, 200 mM dNTPs and 
200 mM of each primer and probe. PCR reactions will then go through 40 cycles 
of 30 sec each at 95° C and 60° C in a Bio-Rad iCycler thermocycler with real 
time detection occurring at 60° C. Data will be analyzed as the change in CT of 
each cytokine transcript to EF1A, allowing comparison of control epithelial cells 
and steroid exposed cells.   
Quantification of changes in receptor expression induced by cytokines will 
be performed using the comparative CT method. Briefly, the amount of target, 
normalized to an endogenous reference and relative to a calibrator will be 
calculated by 2-DDCT with DDCT = (threshold cycle unstimulated gene of interest-
threshold cycle unstimulated housekeeping gene)-(threshold cycle stimulated 
gene of interest-threshold cycle stimulated housekeeping gene). The 
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comparative CT method will be validated by showing that the efficiencies of target 
and reference amplification are equal across a range of mRNA concentrations.  
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RESULTS 
The first patient was enrolled in late September of 2014, and the first 
surgical bronchoscopy procedure took place on the morning of September 22nd, 
2014. However, after an attempt to chemically disrupt the epithelial cell adhesion 
to the brush by soaking the brush in trypsin, there was minimal extraction of cells 
from the brush. Subsequently, we attempted to increase the yield of extracted 
cells by physically dislodging the epithelial cells from the brush using the 
epithelial cell growth medium to repeatedly wash the brush. Nonetheless, the cell 
yield still remained too low to split the cell population and expose the cells to 
dexamethasone. As a result, we were unable to plate cells from the first subject, 
expose the cells to dexamethasone, and obtain any subsequent comparative 
gene expression values in lab. Nonetheless, blood samples, BAL, and the 
entirety of the other experimental samples outlined in the methods section were 
collected; data on these samples will be available when the samples of all 
participating subjects are processed at the conclusion of the study. 
Then enrollment period for the subjects whose data will be included in this 
paper lasted six months from September 2014 to February 2015. By February 
25th, the cut-off date for data collection to be included in this summary, 18 
subjects had enrolled and undergone bronchoscopy. One enrolled subject came 
in discretely on three dates over a two-month period from December 22nd, 2014 
to February 23rd, 2015 for diagnostic bronchoscopy, yielding three sets of 
samples for processing and analysis. Additionally, one enrolled subject who 
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underwent a bronchoscopy did not yield a brush sample. In total, 18 subjects 
underwent bronchoscopies on eight separate Monday surgical days: September 
22nd, 2014, October 27th, 2014, November 10th, 2014, November 24th, 2014, 
December 22nd, 2014, January 26th, 2014, February 9th, 2015, and finally 
February 23rd, 2015. Each surgical day yielded anywhere from one to four 
samples, and the epithelial cells and BAL were both processed immediately upon 
collection. Sixteen of the eighteen subjects yielded samples with bronchoscopy 
brushes that could be processed and utilized for data in the lab. With the three 
samples provided by our first longitudinal subject, we compiled a database with 
epithelial cell steroid responsiveness data on our four target genes from eighteen 
different bronchoscopy brushes. 
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Figure 2: The age distribution of our patient population is spread over an 18-year range. 
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The clinical characteristics of each subject without our patient population 
varied widely from one subject to the next. The age range of patients included 
children as young as six months old, and teenagers as old as 18 (Figure 2). 
Three of our 18 subjects were five years old, and the approximate average 
patient age is six years old. In addition to age, our enrolled subject population 
also varied greatly by asthma phenotype, treatment history, and numerous other 
parameters assessed upon enrollment. The emphasis that this study places on 
assessing a possible connection between steroid sensitivity and airway 
microbiome makes the current pharmaceutical treatments of each subject 
particularly intriguing. Interestingly, 12 of our 18 subjects had recently taken 
regular doses of ICS; within that group of 12 subjects, one subject had 
additionally taken systemic steroids recently. Even more fascinatingly, two of the 
12 subjects who were currently or had recently been on ICS fell within our non-
asthmatic population.  
Within our group of 18 enrolled subjects, one third of the group (6 
subjects) presented with medical histories that classified them as asthmatic, 
while two thirds of the group (12 subjects) had been diagnosed as asthmatics 
before they underwent their diagnostic bronchoscopies. Four of our subjects 
received different diagnoses following the completion of their diagnostic 
bronchoscopy procedures. Two of the previously diagnosed asthmatics were 
reclassified as non-asthmatic controls following their procedures, while two of the 
previously undiagnosed controls were diagnosed as asthmatic subjects following 
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the completion of their bronchoscopies. Information on the peripheral blood and 
airway eosinophil content, two other common markers used to occasionally 
detect the presence of asthma in patients, also yielded useful data. We utilized 
the peripheral blood collected at the time of the procedure to obtain a quantitative 
measurement of eosinophils in each patient. For our purposes, we determined 
that in the peripheral blood, an eosinophil concentration greater than .2 K Cell/µL 
would be classified as eosinophilia. The average peripheral blood eosinophil 
concentration among all of our subjects was .45 K Cell/µL, and nine of our 
enrolled subjects exhibited peripheral blood eosinophil levels higher than this 
threshold. Further, the average concentration among patients who exhibited 
eosinophilia was .79 K Cell/µL. The use of elevated peripheral blood eosinophil 
concentration as a predictor for asthma diagnosis was moderately appropriate; 
eight of the nine patients who exhibited eosinophilia are diagnosed asthmatics. 
Nonetheless, atopy, which is characterized by elevated levels of IgE and the 
tendency to be hyperallergic served as a more “true” predictor of asthmatic 
diagnosis, and all six subjects who exhibited atopy were asthmatics. 
While the full assessment, classification, and analysis of the airway 
microbiome for each subject won’t be completed until the number of enrolled 
subjects has increased, BAL and bronchoscopy brush samples both underwent 
primary processing immediately after their collection. The gene expression 
analysis of the airway epithelial cells from each of the subjects has yielded a 
substantial amount of preliminary data. Often, the wide variance in human 
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phenotype and clinical characteristics leads to a tremendous amount of variance 
in research studies that involve the compilation of human data. In our case, the 
various clinical phenotypes and diagnoses that individuals presented with lead to 
a great deal of variation in the data. This variation is extremely evident in our 
primary assessment of epithelial cell gene expression through quantitative PCR. 
We made numerous adjustments and modifications to our lab techniques over 
the course of our early experiments in an effort to improve the quality of data 
yielded. Specifically, the major variation that we made was to increase the range 
of dexamethasone concentrations that we exposed epithelial cells to following 
bronchoscopy. Initially, we only exposed the epithelial cells to three different 
concentrations of dexamethasone: 10-8 M, 10-7 M, and 10-6 M dexamethasone.  
 
 
 
 
 
 
 
 
 
 
Figure 3: Preliminary Gene Expression Data 
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Subsequently, we used quantitative PCR to compare gene expression in 
epithelial cells exposed to different concentrations of dexamethasone to gene 
expression in unexposed control epithelial cells. However, after examining 
unexpected reversals in the changes of gene expression over these three 
concentrations in the data of some of our early patients (Figure 3), we 
determined that there were quite possibly changes occurring at concentrations of 
dexamethasone lower than our starting experimental dexamethasone 
concentration. Using the data from our fifth subject shown above as an example, 
following a large change in the gene expression of periostin and serpinB2 that 
followed the expected change presented by the literature for steroid sensitive 
individuals, there was an unexpected reverse in the gene expression at 
subsequent higher concentrations of dexamethasone.  
Although it is unexpected that subject data will uniformly follow predicted 
response curves, the reverse that we saw in subject 5 and a number of subjects 
was puzzling. A reverse at higher concentrations raised the possibility that at two 
lower concentrations, we might be able to see a classic dose response curve to 
the steroid exposure. As a result, in an effort to make sure that we were not 
missing any possible key data points in our lab analysis, we expanded our 
dexamethasone concentration range to include the lower concentrations 10-10 M 
dexamethasone and 10-9 dexamethasone. The inclusion of a wider concentration 
range in our lab analysis of the epithelial cells lead to an expansion of our data 
set for each subsequent patient. Nonetheless, before we complete the statistical 
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analysis of the data to determine possible differences within and between groups 
of different clinical phenotypes, it is difficult to accurately assess the significance 
of our current data. 
The variance in the data for SerpinB2, a proposed regulator of the T-
helper 1 (TH1) immune response and promoter of fibrin formation and deposition, 
is readily apparent upon examination of the data in Figure 4. In order to satisfy 
the federal Health Insurance Portability and Accountability Act (HIPPA) 
requirements, we maintain subject anonymity in our databases and labeling. The 
 Table 1: SerpinB2 Expression Data 
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subjects in our study are assigned a number by order of enrollment, and they are 
identified by the shorthand name for our study, ABBA, which stands for the 
Airway Bacteria Burden in Asthma. Analysis of the ΔCT values of each patient 
allowed us to subjectively assess the steroid sensitivity of each patient relative to 
each specific gene of interest. The use of EF1A in our qPCR experiments allows 
us to normalize the level of gene expression in each subject across the range of 
dexamethasone concentrations that we used. EF1A is a translation elongation 
factor that is expressed at constitutively high levels in most cells. As a result, 
regardless of dexamethasone exposure, EF1A should be transcribed at different 
but constantly high levels within epithelial cells of the same individual regardless 
of their growth environment. When running a qPCR, genes that are constitutively 
transcribed at high levels require fewer cycles to be recognized because they 
fluoresce at the thermocycler’s minimal threshold level after a lower number of 
repetitions. The minimum number of cycles that it requires for a gene to fluoresce 
at a high enough level to be recognized by the thermocycler is referred to as the 
concentration threshold, or the CT value. Our calculations utilize the constitutively 
high expression of EF1A as comparative tool to measure the expression levels of 
our target genes. We do so by calculating ΔCT, the difference between the target 
gene’s CT value and the CT value of our housekeeping gene:  
ΔCT = CT Target Gene - CT Housekeeping Gene 
A gene that is not expressed at high levels will require more cycles to reach the 
concentration threshold for recognizable fluorescence in the thermocycler, and 
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will have a higher CT. Therefore, although it is counterintuitive, a gene that is 
expressed at low levels will present with a high CT and as a result, a high ΔCT. In 
the same vein, a decrease in the ΔCT represents an increase in the expression of 
a gene. 
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Figure 4: Graph of FKBP51 Expression Data 
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In graphs such as Figure 4 above, in order to allow the direction of the 
data points (increase or decrease) to serve as a direct visual representation of 
the change in gene expression, it is necessary to invert the values on y-axis so 
that they increase as you rise and decrease as you move down. The above data 
(Figure 4) that we have compiled thus far for serpinB2 suggests that 7 of our 17 
patients are sensitive to dexamethasone suppression of the gene. Discrete 
assessment of each subject in the graphic representation of the same data for 
FKBP51 presented in the graph below suggests that 11 of our 17 subjects are 
sensitive to dexamethasone suppression of FKBP51. 
In addition to the data presented on the two genes above, we have also 
collected similar data for two other genes, CLCA1, and periostin. However, for 
periostin we were unable to obtain the correct primer for our first four enlisted 
subjects. Consequently, our database for periostin only includes expression data 
for the 14 most recently enrolled subjects (Table 2). The data that we have 
compiled for those 14 patients suggests that our patient population may include a 
greater fraction of individuals who are resistant to dexamethasone suppression of 
periostin than sensitive to it. However, since our assessment of sensitivity is 
dictated by entirely subjective analysis of our data, we will not be able to identify 
the true significance of differential responses until we run a number of statistical 
assessments. Nonetheless, our initial data is still very promising. 
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Finally, the data that we compiled for CLCA1 followed the trend of 
showing wide variance in the absence of any conclusive results. Nonetheless, 
the data comparatively suggests that there may be a greater number of 
individuals who show dexamethasone sensitivity to CLCA1 than there are for the 
other genes that we have focused on. The response of CLCA1 to 
dexamethasone in numerous patients suggests that steroids may more readily 
suppress the physiologic effects of CLCA1 compared to our other genes. Overall, 
it seems that there is a great deal of variance in the response of individual 
subjects to each of our specific target genes. 
 
Table 2: Periostin Expression Data 
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Table 3: CLCA1 Expression Data 
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DISCUSSION 
Although the preliminary data exhibits a wide range of variation, it still 
suggests the potential for novel discoveries. However, the full potential of our 
current data will not become truly discernable until we are able to run a more in 
depth statistical analysis of our current findings. Thus far, the majority of our 
analyses of current data have been subjective deductions guided by simple 
statistical parameters. Once we have run tests that can prove true significant 
statistical differences within our database, it will become possible to fully 
understand the value of our current statistics.  
The microbiome samples that we have processed from each enrolled 
subject will be sent for sequencing and assessment once we have increased our 
total subject enrollment so that the samples can be analyzed in large cohorts. As 
a result, we do not have any information on the microbiome diversity nor the 
overall bacterial load for any of our subjects. Nonetheless, although this data will 
essentially constitute almost half of our project’s significance, it is still possible for 
us to draw a number of useful conclusions through the individual analysis of our 
patients’ steroid responsiveness. The compiled database of individual results 
thus far seemed to initially contain too much variance to be useful in the 
determination of any significant differences within or between subject groups of 
specific phenotypes. While the individual graphs of the ΔCT data (Figure 3) are 
moderately useful in the subjective determination of relative sensitivity, 
attempting to represent all of the data from different subjects on one graph 
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confounded the individual significance of data points, and consequentially made 
it difficult to accurately assess any significant differences between specific patient 
groups. In an attempt to make the data in the graphs easier to comprehend, our 
initial idea was to visually represent the subjects of different target phenotypes 
with different colors. For our initial assessment, our three primary groups for 
phenotype comparison were: Asthma vs. No Asthma, Steroid Treatment vs. No 
Steroid Treatment, and Atopy vs. No Atopy. We hoped that by using only two 
colors to represent data points for subjects from either group, we would be able 
to more clearly determine any possible similarities within the group and any 
differences between them (Figure 5). Nonetheless, even with a system that 
allowed easier identification of subjects within our target phenotype cohorts, it 
was still extremely difficult to determine any significant difference between 
groups. 
The two-color representation graphs that we made for our three primary 
clinical phenotype comparison groups were not particular useful in the 
assessment of our data. It became evident that with such great variance, 
attempting to represent such a large number of data points in a single graph 
would convolute the assessment of the graph. Subsequently, we discovered that 
the most efficient way to represent such a large amount of data would be to 
graph the averages of subjects within each group, plot them with the overall 
average of all enrolled subjects, and use these graphs as our primary 
comparisons of differences between groups of different phenotypes. The  
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Figure 5: Two-Color Representation of SerpinB2 Expression Data. Green lines 
connecting data points represent data from subjects with asthma. Blue lines connecting 
data points represent data from subjects without asthma. 
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utilization of this more simple method of graphing our data quickly proved to be 
the most effective way of assessment. Further, it will continue to be exceedingly 
useful as we expand the number of patients enrolled in ABBA. Through these 
more simple graphs, we have been able to make a few more solid conclusions 
on what our current data actually portrays. For example, through Figure 6, we  
	  	  
were able to conclude that there is a potentially significant difference in the 
responsiveness of asthmatic and non-asthmatic patients to dexamethasone 
treatment for the suppression of CLCA1. Although we will not be able to establish 
a definitive significance in this difference until we have completed data analysis, 
our inferred conclusion will give us a good starting point and direction to follow as 
we begin to look towards data analysis. 
Figure 6: Graph of CLCA1 Expression Averages for Asthmatics vs. Non-Asthmatics 
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Our assessments of the simplified average graphs for each of our three 
comparison groups lead to the identification of seven possibly different 
responses between phenotypic groups to dexamethasone suppression of 
specific genes. On average, asthmatics showed differential suppression and 
induction of all four target genes when compared to non-asthmatics. In addition 
patients on steroid treatment on average showed differential suppression of 
periostin, serpinB2, and FKBP51 when compared with patients not on steroids. 
Finally, on average, patients who exhibited atopy showed differential suppression 
of serpinB2 when compared to patients who did not have elevated levels of IgE.  
Human research is amazing. Each individual subject can fall within a 
specific population for one phenotype while simultaneously showing infinite 
variation for numerous other ones. Thus far, our data on asthmatic and non-
asthmatic children has portrayed that variance. Nonetheless, as we continue to 
compile data and look towards statistical assessment, the promise inherent in the 
potential discovery of a differential response to steroids that correlates with 
airway microbiome is extremely encouraging. If we are able to document a 
significant correlation between the response of any of these inflammation related 
genes to dexamethasone and the microbiome present, it is quite possible that we 
could drastically improve current treatment practices. Hopefully, through our 
continued research, we will be able to truly make a positive difference in the way 
that asthma is managed in America. 
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